Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M
This once-weekly injection is intended for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one comorbidity
The rate of fat loss with AOD-9604 is modest compared to aggressive caloric restriction or appetite-suppressing medications
Routine blood tests can help detect any early signs of adverse effects and allow for timely adjustments to your dosage or supplement stack
30.2% for tirzepatide plus placebo, which equates to statistically significant preservation of lean mass of 1.9kg, or 54.9% vs tirzepatide and placebo
Dismiss this notification PatientsLikeMe would like to remind you that your browser is out of date and many features of the website may not function as expected